Jeri Kim

Physician variation in management of low-risk prostate cancer: a population-based cohort study.

Robert J Volk, Yu Shen, Karen E Hoffman, 2014, JAMA internal medicine.

Fingerprinting the circulating repertoire of antibodies from cancer patients

Kim-Anh Do, Christopher J. Logothetis, Massimo Cristofanilli, 2003, Nature Biotechnology.

Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants

Nawaid Usmani, Suzanne Chambers, Martin Eklund, 2018, Nature Communications.

Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products.

Robert A Newman, Gabriela Mendoza, David G Menter, 2005, Cancer research.

Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer

Wenjun Chang, Likun Li, Spyridon Basourakos, 2017, Science Signaling.